Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #58 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 435,863 | 146.5 | 13.7% | 11.0% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 246,660 | 83.9 | 15.3% | 62.7% | 0.32% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 162,454 | 78.2 | 12.2% | 34.6% | 0.79% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 115,910 | 33.3 | 17.3% | 17.2% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 108,736 | 35.4 | 11.2% | -11.0% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,969 | 122.5 | 17.1% | 127.1% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 103,406 | 47.4 | 11.7% | 2.6% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 102,916 | 154.7 | 10.9% | -0.9% | — | 62 | 33 | 71 |
| FDC Limited (this stock) | 5,526 | 18.7 | 11.3% | -25.8% | 1.47% | 79 | 47 | 47 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 668 | 175 | 132 | ₹ |
| March 31, 2026 | 585 | 140 | 103 | ₹ |
| Dec. 31, 2025 | 465 | 36 | 28 | ₹ |
| Sept. 30, 2025 | 473 | 38 | 28 | ₹ |
| June 30, 2025 | 648 | 160 | 121 | ₹ |
| March 31, 2025 | 492 | 53 | 39 | ₹ |
| Dec. 31, 2024 | 464 | 51 | 37 | ₹ |
| Sept. 30, 2024 | 514 | 90 | 72 | ₹ |
| June 30, 2024 | 638 | 163 | 119 | ₹ |
| March 31, 2024 | 462 | 65 | 46 | ₹ |
| Dec. 31, 2023 | 458 | 98 | 79 | ₹ |
| Sept. 30, 2023 | 486 | 93 | 70 | ₹ |
| June 30, 2023 | 536 | 141 | 110 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 2,171 | 375 | 281 |
| March 31, 2025 | 2,108 | 357 | 267 |
| March 31, 2024 | 1,943 | 396 | 305 |
| March 31, 2023 | 1,784 | 258 | 194 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 200 | -110 | -93 | 187 | 14 |
| March 31, 2025 | 318 | -200 | -92 | 97 | 221 |
| March 31, 2024 | 221 | -17 | -202 | 93 | 127 |
| March 31, 2023 | 155 | 11 | -180 | 113 | 42 |
| March 31, 2022 | 162 | -145 | -10 | 133 | 29 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 2,919 | 2,485 | 2,469 | 0 | 0 | 1,133 | 364 | 49 | 952 | 355 |
| March 31, 2025 | 2,714 | 2,281 | 2,265 | 0 | 0 | 1,085 | 362 | 51 | 848 | 375 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
